Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years
Want more insights? Join Grow With Caliber - our career elevating newsletter and get our take on the future of work delivered weekly.
